IDEXX Laboratories (IDXX) 주식 개요
는 미국 및 국제적으로 반려동물 수의학, 가축 및 가금류, 낙농 및 수질 검사 산업을 위한 제품을 개발, 제조 및 유통하는 회사입니다. 자세히 보기
IDXX Community Fair Values
Create NarrativeSee what 59 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
IDEXX Laboratories, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$567.44 |
| 52주 최고가 | US$769.98 |
| 52주 최저가 | US$513.02 |
| 베타 | 1.55 |
| 1개월 변동 | 0.95% |
| 3개월 변동 | -2.68% |
| 1년 변동 | 10.27% |
| 3년 변동 | 2.32% |
| 5년 변동 | -18.21% |
| IPO 이후 변동 | 59,926.74% |
최근 뉴스 및 업데이트
Seeking Alpha • Jul 07
IDEXX Laboratories Does Not Need More Vet Visits--But It Needs More Tests Per Visit
Summary IDEXX Laboratories (IDXX) is rated Hold, as its premium valuation (~38x 2026E EPS) already assumes strong recurring revenue and diagnostics growth. IDXX is growing diagnostics revenue despite declining veterinary visits, leveraging inVue Dx and Cancer Dx to expand test volumes and market share. inVue Dx and Cancer Dx offer credible market expansion opportunities, but recurring consumables adoption and reference-lab volume growth remain unproven at scale. Scenario analysis shows modest base case upside and meaningful downside risk if consumables adoption or margin expansion underperform expectations. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 01
IDXX: Expanded Diagnostics And Reset Expectations Will Support Future Shareholder Value
Analysts have trimmed their price targets on IDEXX Laboratories by roughly $40. This reflects slightly lower fair value estimates, a modestly reduced revenue growth outlook, and a lower assumed future P/E multiple.
내러티브 업데이트 • Jun 17
IDXX: Cooler Street Views Will Meet Raised Outlook And Execution Risks
Analysts have trimmed their price targets on IDEXX Laboratories stock, with the updated fair value estimate now aligned around $530. This reflects a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a marginally lower future P/E multiple.분석 기사 • Jun 17
IDEXX Laboratories (IDXX) Stock Could Be 23.6% Undervalued as Growth Narrative Faces P/E Test
IDEXX Laboratories (IDXX) stock has attracted fresh attention after recent price moves, with a last close of $573 and mixed short term returns that include a gain over the past month but a decline year to date. See our latest analysis for IDEXX Laboratories. Against a backdrop of mixed trading, IDEXX Laboratories has seen its share price recover in the past month, with a 30 day share price return of 8.36% contrasting with a year to date decline of 14.48%. The 1 year total shareholder return...Recent updates
Seeking Alpha • Jul 07
IDEXX Laboratories Does Not Need More Vet Visits--But It Needs More Tests Per Visit
Summary IDEXX Laboratories (IDXX) is rated Hold, as its premium valuation (~38x 2026E EPS) already assumes strong recurring revenue and diagnostics growth. IDXX is growing diagnostics revenue despite declining veterinary visits, leveraging inVue Dx and Cancer Dx to expand test volumes and market share. inVue Dx and Cancer Dx offer credible market expansion opportunities, but recurring consumables adoption and reference-lab volume growth remain unproven at scale. Scenario analysis shows modest base case upside and meaningful downside risk if consumables adoption or margin expansion underperform expectations. Read the full article on Seeking Alpha내러티브 업데이트 • Jul 01
IDXX: Expanded Diagnostics And Reset Expectations Will Support Future Shareholder Value
Analysts have trimmed their price targets on IDEXX Laboratories by roughly $40. This reflects slightly lower fair value estimates, a modestly reduced revenue growth outlook, and a lower assumed future P/E multiple.내러티브 업데이트 • Jun 17
IDXX: Cooler Street Views Will Meet Raised Outlook And Execution Risks
Analysts have trimmed their price targets on IDEXX Laboratories stock, with the updated fair value estimate now aligned around $530. This reflects a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a marginally lower future P/E multiple.분석 기사 • Jun 17
IDEXX Laboratories (IDXX) Stock Could Be 23.6% Undervalued as Growth Narrative Faces P/E Test
IDEXX Laboratories (IDXX) stock has attracted fresh attention after recent price moves, with a last close of $573 and mixed short term returns that include a gain over the past month but a decline year to date. See our latest analysis for IDEXX Laboratories. Against a backdrop of mixed trading, IDEXX Laboratories has seen its share price recover in the past month, with a 30 day share price return of 8.36% contrasting with a year to date decline of 14.48%. The 1 year total shareholder return...
내러티브 업데이트 • Jun 03
IDXX: Recurring Diagnostics And AI Cancer Testing Will Support Future Earnings Power
Analysts have trimmed IDEXX Laboratories' fair value estimate by $18 to $805. This reflects updated views on growth, profitability and P/E assumptions following a series of recent price target resets and a neutral initiation on the stock.내러티브 업데이트 • May 18
IDXX: Cooler Street Views Will Meet Cancer Diagnostics And Margin Execution Focus
For IDEXX Laboratories, the analyst price target has shifted modestly lower to about $530 from roughly $537 as analysts factor in adjusted assumptions for growth, profitability and future P/E multiples following a series of recent target cuts and a new neutral initiation. Analyst Commentary Recent Street research on IDEXX Laboratories points to a more cautious tone, with several price target cuts and a neutral initiation helping pull the average target lower.내러티브 업데이트 • May 01
IDXX: Cancer Diagnostics Execution And Margin Discipline Will Guide Cooler Yet Fair Outlook
The updated analyst price target for IDEXX Laboratories has been reduced by about $19, reflecting slightly higher discount assumptions, modestly different margin expectations, and a lower future P/E multiple cited across recent research from several firms. Analyst Commentary Recent Street research for IDEXX Laboratories has leaned cautious, with several bearish analysts lowering their price targets by ranges of about $25 to $100.내러티브 업데이트 • Apr 16
IDXX: Recurring Diagnostics And Cancer Testing Will Support Future Earnings Power
Analysts have trimmed their average price target on IDEXX Laboratories by $100. This reflects a more cautious stance, even as updated assumptions for discount rate, revenue growth, profit margins and future P/E remain broadly aligned with prior expectations.내러티브 업데이트 • Apr 01
IDXX: Cancer Diagnostics Execution And Margin Resilience Will Shape Fairly Valued Outlook
For IDEXX Laboratories, the updated analyst price target has shifted from about $579 to roughly $556 as analysts adjust their models for slightly different revenue growth and P/E assumptions, while also acknowledging a modestly higher profit margin outlook. Analyst Commentary Recent research updates show a series of lower price targets for IDEXX Laboratories, with bearish analysts trimming their expectations by amounts ranging from about $20 to roughly $100.내러티브 업데이트 • Mar 18
IDXX: Recurring Diagnostics And Cancer Testing Will Support Long Term Earnings Power
Narrative Update The analyst price target for IDEXX Laboratories has been reduced by a series of cuts totaling $125, with analysts pointing to updated assumptions for revenue growth, profit margins, and future P/E as key drivers of the change. Analyst Commentary Recent Street research on IDEXX Laboratories has centered on revised price targets, with several firms updating their models to reflect new assumptions for revenue growth, profitability, and P/E.내러티브 업데이트 • Mar 04
IDXX: Recurring Diagnostics And Cancer Testing Pipeline Will Support Future Earnings Power
Analysts have trimmed their price target on IDEXX Laboratories by $27 to $823, citing updated assumptions around discount rates, long term growth, and future P/E expectations. Analyst Commentary Recent research commentary on IDEXX Laboratories has centered on recalibrated price targets that incorporate updated assumptions for discount rates, long term growth, and future P/E expectations.내러티브 업데이트 • Feb 18
IDXX: New Diagnostics Pipeline And Margin Outlook Will Support Future Shareholder Value
The analyst price target for IDEXX Laboratories has been trimmed by about $4.60 as analysts factor in slightly more measured revenue growth assumptions, a modestly lower future P/E multiple, and a somewhat higher expected profit margin. Analyst Commentary Recent Street research has clustered around lower price targets for IDEXX Laboratories, with cuts of about US$20 to US$50 in quick succession.내러티브 업데이트 • Feb 04
IDXX: Recurring Diagnostics And Cancer Testing Pipeline Will Support Long Term Earnings Power
Analysts have reduced their price targets on IDEXX Laboratories by $20 to $30, reflecting updated assumptions around revenue growth, profit margins, and future P/E multiples, while maintaining a broadly similar view of fair value. Analyst Commentary Bullish analysts appear to see the recent price target cuts as more of a recalibration than a shift in their overall thesis on IDEXX Laboratories.내러티브 업데이트 • Jan 20
IDXX: Rich P/E Leaves Little Room For Cancer Diagnostics Execution Missteps
Analysts have raised their fair value estimate for IDEXX Laboratories from about US$497 to about US$579, citing higher modeled revenue growth, slightly stronger profit margins, a richer future P/E, and increased confidence in the company's product pipeline and recurring diagnostics growth following recent Q3 results and guidance updates. Analyst Commentary Street research after the Q3 update centers on two themes: confidence in IDEXX Laboratories' recurring diagnostics growth and product pipeline, and questions about how much of that strength is already reflected in the share price.내러티브 업데이트 • Jan 06
IDXX: Recurring Diagnostics And Cancer Testing Pipeline Will Support Premium Earnings Power
Analysts have lifted their price targets on IDEXX Laboratories into a US$750 to US$805 range, citing a strong Q3 print, increased 2025 guidance, and what they describe as a compelling diagnostics pipeline along with solid recurring revenue trends as key supports for higher valuations. Analyst Commentary Recent research updates around IDEXX Laboratories cluster around a similar theme, with bullish analysts pointing to a strong Q3, raised 2025 guidance, and a diagnostics portfolio they see as well positioned in current markets.내러티브 업데이트 • Dec 16
IDXX Recurring Diagnostics Strength Will Support Premium Earnings Power Ahead
Our updated fair value estimate for IDEXX Laboratories has increased to $850 from $785, as analysts highlight a stronger than expected Q3 performance, accelerating recurring diagnostic revenue growth, and a robust innovation pipeline that supports slightly higher long term growth and margin assumptions despite a modestly higher discount rate. Analyst Commentary Recent Street research reflects a broadly constructive stance on IDEXX Laboratories following its stronger than expected Q3 results and raised 2025 guidance.내러티브 업데이트 • Dec 02
IDXX: Recent Performance and Pipeline Progress Will Support Long-Term Shareholder Value
The average analyst price target for IDEXX Laboratories has been raised, reflecting a series of upward revisions. Several targets now surpass $750, as analysts cite stronger-than-expected Q3 results and a constructive outlook on growth, innovation, and recurring revenues.내러티브 업데이트 • Nov 18
IDXX: Future Revenue Acceleration Will Drive Premium Multiples and Shareholder Returns
The analyst price target for IDEXX Laboratories has increased significantly, rising by over $50 to approximately $755. Analysts cite a stronger growth outlook, durable pricing, and robust quarterly results as supporting factors for higher valuations.내러티브 업데이트 • Nov 03
IDXX: Expanding Installed Base Will Drive Accelerating Business Momentum Ahead
The consensus analyst price target for IDEXX Laboratories has increased by over $22. This reflects growing optimism fueled by expectations of accelerating recurring revenue growth, stronger visit trends, and expanding product adoption in the company's core business lines.내러티브 업데이트 • Oct 20
Advanced Diagnostics And International Expansion Will Define Future Opportunity
The analyst fair value estimate for IDEXX Laboratories was adjusted downward to $679.92 from $695.09. Analysts highlighted accelerated consumables growth and an expanding installed base, which support long-term growth potential as market conditions normalize.분석 기사 • Aug 16
Earnings Not Telling The Story For IDEXX Laboratories, Inc. (NASDAQ:IDXX) After Shares Rise 25%
NasdaqGS:IDXX 1 Year Share Price vs Fair Value Explore IDEXX Laboratories's Fair Values from the Community and select...분석 기사 • Aug 07
IDEXX Laboratories, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
NasdaqGS:IDXX 1 Year Share Price vs Fair Value Explore IDEXX Laboratories's Fair Values from the Community and select...내러티브 업데이트 • Aug 06
Advanced Diagnostics And International Expansion Will Define Future Opportunity
IDEXX Laboratories’ consensus price target has been sharply raised, reflecting strengthened revenue growth forecasts and a higher future P/E multiple, with fair value increasing from $542.55 to $657.55. What's in the News IDEXX Laboratories raised 2025 earnings guidance, increasing revenue outlook to $4,205–$4,280 million (up $90 million at midpoint) and EPS to $12.40–$12.76 (up $0.40 at midpoint), reflecting strong recurring diagnostics revenue, higher inVue Dx instrument placements, and favorable foreign exchange.분석 기사 • Jul 23
At US$532, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Let's talk about the popular IDEXX Laboratories, Inc. ( NASDAQ:IDXX ). The company's shares saw a significant share...Seeking Alpha • Apr 14
IDEXX Laboratories: I Love The Business, Not The Stock Price
Summary IDEXX Laboratories is a business that is supported by strong tailwinds, has a sticky business model with predictable, recurring revenue, all supported by an innovation-led growth strategy. There are some concerns like the way management is allocating capital, the tariff risks involving China, lower ROIC, and a declining growth rate. My main concern is with the valuation, as it is hard to justify an earnings multiple in excess of 30 when the growth rate is in the low-teens. Read the full article on Seeking AlphaSeeking Alpha • Mar 12
IDEXX Laboratories: A Top Dog In The Pet Care Market
Summary The pet care industry is growing, with increasing pet ownership and spending, especially in emerging markets, providing IDEXX with significant growth opportunities. IDEXX Laboratories is the market leader with a highly profitable business model, operating leverage, and recurring revenues. Once a customer starts using an IDEXX instrument, it is tied to the IDEXX ecosystem. In the short term, revenue growth will be driven by the recent launch of the IDEXX inVue Dx instrument, the development of the oncology market, and the cloud-based software. Given IDEXX's competitive advantages, market growth potential, and current fair valuation, I initiate coverage with a buy rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 10
IDEXX Laboratories And Its Real Value
Summary IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years. This article focuses on the fundamentals, the real value versus the current share price, and if IDEXX Laboratories is currently worth investing in. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
IDEXX Laboratories Q3: Weak End-Market Demand Continues
Summary I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth. IDEXX's future growth prospects remain promising, but current stock prices do not fully account for weak end-market demands, justifying the 'Sell' rating. Read the full article on Seeking Alpha
새로운 내러티브 • Aug 19
Global Expansion And Innovative Products Propel Revenue And Margin Growth Amidst Challenges
IDEXX's international and innovative product growth, like the inVue Dx Cellular Analyzer, fuels potential revenue and market share increases globally.Seeking Alpha • Aug 12
IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Summary IDEXX reported lower full-year organic revenue growth due to reduced U.S. clinical visits. Weak consumer sentiment and ongoing staffing challenges may continue to impact clinical visits in the near future. Launch of new menu expansion for Catalyst platform may drive growth in diagnostic business, but the stock remains overvalued. Read the full article on Seeking Alpha주주 수익률
| IDXX | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 0.7% | -1.6% | -2.0% |
| 1Y | 10.3% | -18.4% | 17.4% |
수익률 대 산업: IDXX은 지난 1년 동안 -18.4%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: IDXX은 지난 1년 동안 17.4%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| IDXX volatility | |
|---|---|
| IDXX Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: IDXX는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: IDXX의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1983 | 11,000 | Mike Erickson | www.idexx.com |
는 미국 및 국제적으로 반려동물 수의학, 가축 및 가금류, 낙농 및 수질 검사 산업을 위한 제품을 개발, 제조 및 유통하는 회사입니다. 이 회사는 세 가지 부문으로 운영됩니다: 반려동물 그룹; 수질 제품; 가축, 가금류 및 낙농. 이 회사는 현장 진단 솔루션, 혈액 및 소변 화학, 혈액학, 면역 분석, 소변 분석, 세포학/형태학 및 응고 분석기, SNAP 신속 분석 테스트 키트를 제공합니다.
IDEXX Laboratories, Inc. 기초 지표 요약
| IDXX 기초 통계 | |
|---|---|
| 시가총액 | US$44.76b |
| 순이익 (TTM) | US$1.10b |
| 매출 (TTM) | US$4.45b |
40.9x
주가수익비율(P/E)10.1x
주가매출비율(P/S)IDXX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| IDXX 손익계산서 (TTM) | |
|---|---|
| 매출 | US$4.45b |
| 매출원가 | US$1.69b |
| 총이익 | US$2.76b |
| 기타 비용 | US$1.66b |
| 순이익 | US$1.10b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 04, 2026
| 주당순이익(EPS) | 13.88 |
| 총이익률 | 62.05% |
| 순이익률 | 24.63% |
| 부채/자본 비율 | 63.0% |
IDXX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/19 12:51 |
| 종가 | 2026/07/17 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
IDEXX Laboratories, Inc.는 25명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Glen Santangelo | Barclays |
| Navann Ty Dietschi | BNP Paribas |
| Michael Ryskin | BofA Global Research |